Tumour heterogeneity is increasingly recognized as a major obstacle to therapeutic success across neuro-oncology. Gliomas are characterized by distinct combinations of genetic and epigenetic alterations, resulting in complex interactions across multiple molecular pathways. Predicting disease evolution and prescribing individually optimal treatment requires statistical models complex enough to capture the intricate (epi)genetic structure underpinning oncogenesis. Here, we formalize this task as the inference of distinct patterns of connectivity within hierarchical latent representations of genetic networks. Evaluating multi-institutional clinical, genetic and outcome data from 4023 glioma patients over 14 years, across 12 countries, we employ Bayesian generative stochastic block modelling to reveal a hierarchical network structure of tumour genetics spanning molecularly confirmed glioblastoma, IDH-wildtype; oligodendroglioma, IDH-mutant and 1p/19q codeleted; and astrocytoma, IDH-mutant. Our findings illuminate the complex dependence between features across the genetic landscape of brain tumours and show that generative network models reveal distinct signatures of survival with better prognostic fidelity than current gold standard diagnostic categories.
Background The success of social distancing implementations of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) depends heavily on population compliance. Mathematical modelling has been used extensively to assess the rate of viral transmission from behavioural responses. Previous epidemics of SARS-Cov-2 have been characterised by superspreaders, a small number of individuals who transmit a disease to a large group of individuals, who contribute to the stochasticity (or randomness) of transmission compared to other pathogens such as Influenza. This growing evidence proves an urgent matter to understand transmission routes in order to target and combat outbreaks. Objective To investigate the role of superspreaders in the rate of viral transmission with various levels of compliance. Method A SEIRS inspired social network model is adapted and calibrated to observe the infected links of a general population with and without superspreaders on four compliance levels. Local and global connection parameters are adjusted to simulate close contact networks and travel restrictions respectively and each performance assessed. The mean and standard deviation of infections with superspreaders and non-superspreaders were calculated for each compliance level. Results Increased levels of compliance of superspreaders proves a significant reduction in infections. Assuming long-lasting immunity, superspreaders could potentially slow down the spread due to their high connectivity. Discussion The main advantage of applying the network model is to capture the heterogeneity and locality of social networks, including the role of superspreaders in epidemic dynamics. The main challenge is the immediate attention on social settings with targeted interventions to tackle superspreaders in future empirical work. Conclusion Superspreaders play a central role in slowing down infection spread following compliance guidelines. It is crucial to adjust social distancing measures to prevent future outbreaks accompanied by population-wide testing and effective tracing.
Gliomas typically exhibit a spectrum of genetic mutations, reflecting multiple, potentially complex interactions across distinct molecular pathways. Predicting disease evolution and prescribing individually optimal treatment plausibly requires statistical models complex enough to capture the intricate genetic structure underpinning oncogenesis. Here we formalize this task as the discovery of distinct patterns of connectivity within network representations of the interactions between genetic loci. Evaluating multi-institutional clinical, genetic, and outcome data from 4023 consecutive patients over a 14-year period, we employ Bayesian stochastic block modelling to reveal a hierarchical network structure of tumour genetic interactions spanning glioblastoma, oligodendroglioma, and astrocytoma. We show that this structure not only identifies diagnosis but predicts patient survival with greater fidelity than the latest WHO tumour classification or linear models of genetic features. For example, a diagnosis of IDH- wildtype glioblastoma yielded median survivals varying from 289 days in patients with the signature of marked EGFR amplification, MGMT methylation, and histone mutations, to 425 days in those with the signature of TERT mutations, histone, and EGFR wild-types, and variable MGMT methylation. Our findings illuminate the complex dependence between features across the genetic landscape of brain tumours and show network analysis reveals distinct signatures of survival with better prognostic fidelity than current gold standard diagnostic categories, paving the way for personalised prognostication.
Tumor heterogeneity is increasingly recognized as a major obstacle to therapeutic innovation across neuro-oncology. Gliomas typically exhibit a spectrum of possible genetic mutations, reflecting multiple, potentially complex interactions across distinct molecular pathways. Predicting disease evolution and prescribing individually optimal treatment plausibly requires statistical models complex enough to capture the intricate genetic structure underpinning oncogenesis. Here we formalize this task as the discovery of distinct patterns of connectivity within network representations of the interactions between genetic loci. Evaluating multi-institutional clinical, genetic, and outcome data from 7847 consecutive patients over a 14-year period, we employ Bayesian stochastic block modelling to reveal a hierarchical network structure of tumor genetic interactions spanning (molecularly confirmed) IDH-wildtype glioblastoma, IDH-mutant oligodendroglioma and astrocytoma. We show that this structure not only identifies the patients’ diagnosis, but predicts individual survival with greater fidelity (Cox’s proportional hazard cross-validated (CPH-CV) concordance = 0.78; Bayesian 12, 24 and 36-month survival models = R2 0.31, 0.40 and 0.46, respectively) than the latest WHO tumor classification (CPH-CV concordance = 0.77; Bayesian 12, 24 and 36-month survival models = R2 0.26, 0.36 and 0.39, respectively) or linear models of genetic features (CPH-CV concordance = 0.76; Bayesian 12, 24 and 36-month survival models = R2 0.26, 0.35 and 0.37, respectively). For example, a diagnosis of IDH-wildtype glioblastoma yielded median survivals varying from 289 days in patients with the signature of marked EGFR amplification, MGMT methylation, and histone mutations, to 425 days in those with the signature of TERT mutations, histone and EGFR wild-types, and variable MGMT methylation. These findings suggest network-based analysis can reveal distinct signatures of survival with better prognostic fidelity than current gold standard diagnostic categories.
About Me
Medic @UCL. Interests in medtech, AI, healthcare innovation
Medic @UCL. Interests in medtech, AI, healthcare innovation